The U.S. Food and Drug Administration (FDA) has granted GW Pharmaceuticals Plc's experimental cannabis-derived epilepsy drug "orphan" status for a third group of patients affected by a rare form of the disease.

GW said on Thursday that its drug, Epidiolex, had been granted the status for the treatment of tuberous sclerosis complex (TSC), a rare genetic disorder that causes epilepsy in about 80 percent to 90 percent of the patients afflicted with it.

TSC is the third orphan indication that GW is targeting within its Epidiolex clinical development program.

Orphan status is granted to drugs aimed at treating rare diseases, giving the developer incentives such as a seven-year marketing exclusivity in the United States.

Click here to read the rest of the article

Reuters ~

Recent News Articles

Thursday July 18

First Ever Pot Cafe To Open In West Hollywood - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

The first ever cannabis cafe in the nation will open later this year in West…

327 hits

Thursday July 18

Ohio lawmakers vote to decriminalize CBD oil, hemp products - Cannabis News

in Cannabis News

by Bruce Kennedy - Editor in Chief

The Ohio House on Wednesday voted 88-3 in favor of legislation that would move Ohio…

674 hits

Thursday July 18

The marijuana industry needs innovation to thrive - Cannabis News

in Hi-Tech

by Bruce Kennedy - Editor in Chief

Marijuana companies are facing enormous pressure to innovate.

315 hits

Friday July 19

Louisiana 'weeks’ away from medical marijuana rollout - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

Medical marijuana could finally be available for Louisiana’s sickest patients in “the next few weeks,"…

288 hits

Friday July 19

Hype, Hops, and a Lot of Hope: Inside the Billion-Dollar Weed Drink Gamble - Cannabis…

in Finance

by Bruce Kennedy - Editor in Chief

With the exception of CBD, few cannabis products have received as much corporate hype as…

333 hits